GRPR and neoplasm: A comparison in terms of ex vivo tumor-to-organ ratios between [99mTc]Tc-maSSS-PEG2-RM26 performance 3 h pi and other reported 99mTc-labelled GRPR antagonists at this time point showed comparable tumor-to-blood, tumor-to-liver, tumor-to-kidney, tumor-to-intestines and tumor-to-muscle ratios for [99mTc]Tc-maSSS-PEG2-RM26 and [99mTc]Tc-Demobesin 1, [99mTc]Tc-4 [36], [99mTc]Tc-DB7, [99mTc]Tc-DB13 and [99mTc]Tc-DB14 [42], with the exception of a two-fold higher tumor-to-muscle ratio for [99mTc]Tc-Demobesin 1.